Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
The highly-anticipated fifth edition is here! Get the must-have resource for achieving compliance with medical device regulations.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Last week, the US Food and Drug Administration announced the release of a new report, FDA Science Moving Forward, showcasing the agency's scientific advancements since 2007.
In 2007, FDA's Science Board released a report, FDA Science and Mission at Risk, which predicted that "rapid developments" in emerging scientific disciplines such as genomics, personalized medicine and tissue- and stem cell-based therapy would pose increasingly complex scientific challenges to the agency.
To illustrate the scientific challenges faced by the agency, the report gives examples of emerging technologies that it has begun to encounter:
"FDA is receiving an increasing number of stem cell-based products for evaluation.An FDA advisory committee has considered medical interventions involving manipulation of the mitochondrial genome that would prevent the transmission of severe mitochondrial diseases.FDA is seeing a growing number of submissions for medical devices that use computer simulations to describe how the device performs.FDA is increasingly using next-generation sequencing to identify sources of microbial contamination in food and other regulated products.FDA is receiving a growing number of regulatory submissions in which genomics data are considered in the approval and labeling supporting the development of genomically targeted therapeutics to further personalize medicine."
To keep pace with scientific innovation, the 2007 FDA Amendments Act created a new office for scientific oversight for the agency, the Office of the Chief Scientist. Since then, FDA has created several other offices to bolster its ability to meet its mandate, including the Office of Regulatory Science and the Office of Scientific Professional Development.
In 2010, FDA launched its Advancing Regulatory Science Initiative to "transform the way medical products are developed, evaluated, and manufactured [in] all FDA-regulated activities and every dimension of regulatory science, including postmarket surveillance."
The agency says it uses regulatory science to develop and apply "the best available scientific data, knowledge, methods, and tools to reduce uncertainty and make regulatory evaluation and decision-making more efficient and consistent."
In the report, FDA says it knows it must be vigilant to continue to achieve its goals, and must:
"Remain current on new science and technology, so FDA can use the best available tools to evaluate existing and new products""Make innovative contributions to new science and technology that reflect [the agency's] knowledge of the regulatory needs and limiting factors in product development""Remain positioned to respond rapidly to public health emergencies involving … regulated products"
In 2011, the agency built on top of its Advancing Regulatory Science Initiative by crafting a Strategic Plan for Advancing Regulatory Science.
The plan originally outlined eight scientific priority areas, though a ninth was added later in 2013:
modernize toxicology to enhance product safetystimulate innovation in clinical evaluations and precision medicine to improve product development and patient outcomessupport new approaches to improve product manufacturing and qualityensure FDA readiness to evaluate innovative and emerging technologiesharness diverse data through information sciences to improve health outcomesimplement a new prevention-focused food safety system to protect public healthfacilitate development of medical countermeasures to protect against threats to us and global health and securitystrengthen social and behavioral science to help consumers and professionals make informed decisions about regulated productsstrengthening the global product safety net
While FDA's Science Board has been around since 1992, it has "become increasingly engaged in programmatic reviews of FDA's product center and office regulatory science programs."
Some of the programs the Science Board has reviewed include pharmacovigilance programs at the Center for Drug Evaluation and Research (CDER) and the Center for Devices and Radiological Health (CDRH), as well as the Center for Biologics Evaluation and Research's (CBER) postmarketing safety programs and the National Antimicrobial Resistance Monitoring System.
FDA Voice, FDA Science Moving Forward
Tags: Regulatory science, Science Board